22.69
Sanara Medtech Inc stock is traded at $22.69, with a volume of 59,981.
It is up +3.68% in the last 24 hours and up +7.74% over the past month.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
See More
Previous Close:
$21.89
Open:
$21.91
24h Volume:
59,981
Relative Volume:
1.09
Market Cap:
$207.93M
Revenue:
$103.14M
Net Income/Loss:
$-5.82M
P/E Ratio:
-5.213
EPS:
-4.3526
Net Cash Flow:
$2.14M
1W Performance:
-0.13%
1M Performance:
+7.74%
6M Performance:
-9.96%
1Y Performance:
-20.86%
Sanara Medtech Inc Stock (SMTI) Company Profile
Name
Sanara Medtech Inc
Sector
Industry
Phone
817-529-2300
Address
1200 SUMMIT AVE, FORT WORTH
Compare SMTI vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
SMTI
Sanara Medtech Inc
|
22.69 | 200.55M | 103.14M | -5.82M | 2.14M | -4.3526 |
|
ISRG
Intuitive Surgical Inc
|
417.07 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
|
BDX
Becton Dickinson Co
|
145.16 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
65.84 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
37.09 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
193.94 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Sanara Medtech Inc Stock (SMTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Lake Street | Buy |
| Mar-26-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| May-20-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jun-30-21 | Initiated | Cantor Fitzgerald | Overweight |
Sanara Medtech Inc Stock (SMTI) Latest News
Sanara MedTech Inc. (SMTI) Tops Q3 Earnings Estimates - MSN
Sanara MedTech Shareholders Reaffirm Board and Governance Policies - TipRanks
Sanara MedTech (SMTI) investors approve board, auditor and 3-year say-on-pay cycle - Stock Titan
Responsive Playbooks and the SMTI Inflection - Stock Traders Daily
[Form 4] Sanara MedTech Inc. Insider Trading Activity - Stock Titan
Sanara MedTech (SMTI) director receives 4,154 restricted shares, total holdings 26,858 - Stock Titan
Sanara MedTech (SMTI) director Ronald Nixon receives 4,154 restricted shares grant - Stock Titan
Sanara MedTech director granted 4,385 restricted shares | SMTI Insider Trading - Stock Titan
Sanara MedTech Ends Catalyst Advisory Deal, Refocuses Strategy - TipRanks
Sanara Medtech Terminates Services Agreement With Catalyst Effective June 2 - TradingView
Sanara MedTech Ends Advisory Services Agreement With The Catalyst Group Amid Strategy Shift - TradingView
Sanara MedTech (NASDAQ: SMTI) terminates Catalyst advisory agreement - Stock Titan
Sanara MedTech (SMTI) Q1 2026 Earnings Transcript - AOL.com
Sanara MedTech (SMTI) Q1 2026 Earnings Transcript - The Motley Fool
SMTI Stock Price, Quote & Chart | SANARA MEDTECH INC (NASDAQ:SMTI) - ChartMill
Sanara MedTech Inc. (SMTI) Slides as Support Test Looms; Medtech Sector Sentiment WeighsIchimoku Entry - The Legal Advocate
Sanara MedTech (SMTI) Falls 4.2% as Selling Pressure Intensifies Near SupportFloat Adjusted Cap - newsline.com
Sanara MedTech (SMTI) Gains 1.75% as Stock Tests Key Resistance LevelGEX Level - newsline.com
Sanara MedTech (SMTI) Q4 2025 Earnings Transcript - AOL.com
Understanding the Setup: (SMTI) and Scalable Risk - Stock Traders Daily
Sanara MedTech Dips After Swing to Profit - Bez Kabli
Sanara MedTech (SMTI) Edges Lower Amid Modest Trading, Holds Above Key SupportMarket Leader Picks - The Legal Advocate
Bronstein, Gewirtz & Grossman, LLC Encourages Sanara MedTech Inc. (SMTI) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
How The Sanara MedTech (SMTI) Narrative Is Shifting As The US$34 Target Stays Put - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sanara MedTech Inc. (SMTI) And Encourages Shareholders to Connect - ACCESS Newswire
Sanara MedTech (SMTI) Q1 2026 Earnings: EPS $0.05 Beats EstimatesReturn On Equity - The Legal Advocate
Sanara MedTech (SMTI) Q1 2026 Earnings Beat: Revenue $N/A, EPS $0.05Viral Trade Signals - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc.SMTI - PR Newswire
Pomerantz LLP investigates Sanara MedTech for p... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Sanara MedTech Inc. (SMTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sanara MedTech (SMTI) CEO reports share withholding to cover tax on vested stock - Stock Titan
Sanara MedTech Inc. (SMTI) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
The Technical Signals Behind (SMTI) That Institutions Follow - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Sanara MedTech Inc - The National Law Review
2026-05-15 | Bronstein, Gewirtz & Grossman, LLC Encourages Sanara MedTech Inc. (SMTI) Stockholders to Inquire about Securities Investigation | NDAQ:SMTI | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Sanara MedTech: From Cash Burner To Profitable Growth (NASDAQ:SMTI) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sanara MedTech Inc. (SMTI) And Encourages Investors to Reach Out - ACCESS Newswire
Sanara MedTech Inc. (NASDAQ:SMTI) Q1 2026 Earnings Call Transcript - Insider Monkey
Sanara MedTech Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Sanara outlines Q2 2026 net revenue of $28.5M-$29.5M while reaffirming $116M-$121M full-year outlook - MSN
Lake Street Maintains Sanara MedTech(SMTI.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Sanara MedTech (SMTI) posts Q1 2026 profit as revenue reaches $27.8M - Stock Titan
Sanara MedTech Inc (SMTI) Q1 2026 Earnings Call Highlights: Stro - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sanara MedTech Inc. (SMTI) And Encourages Stockholders to Reach Out - ACCESS Newswire
Sanara MedTech (SMTI) Reports Strong Q1 Revenue Growth and Impro - GuruFocus
2026-05-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sanara MedTech Inc. (SMTI) And Encourages Stockholders to Reach Out | NDAQ:SMTI | Press Release - Stockhouse
Earnings call transcript: Sanara MedTech Q1 2026 beats EPS expectations, stock surges - Investing.com
Earnings call transcript: Sanara MedTech Q1 2026 beats EPS expectations, stock surges By Investing.com - Investing.com South Africa
Transcript: Sanara MedTech Q1 2026 Earnings Conference Call - Benzinga
Sanara MedTech Sees 2Q Rev $28.5M-$29.5M >SMTI - Moomoo
Sanara Medtech Inc Stock (SMTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):